Although further research is needed, these studies strongly indicate that FXR is a negative modulator of hepatic cell hyperproliferation, ergo therapeutic modulation of FXR and SOCS3 could be profitable in patient with liver carcinoma, namely, which provides a new view about hepatic cancer treatment when targeting this FXR-SOCS3 signaling. Here, SOCS3 is linked to hepatocellular carcinoma.